Anavex Life Sciences Corp (AVXL)

[PeterKarol]

The paper is limited to reporting the performance of Blarcamesine only in terms of the natural distribution theory. That maybe a proper way to express data among scientists but in my analysis that is based on the initial phase 2a distribution things are a bit complicated. I believe the distribution is bimodal, the evidence points to it especially since the company has tried to expressed the data in terms of Odds Ratio. Though Odds Ratio is a standard statistical measurement technic it is a strange creature to habituated investors public to mean and SD that describe perfectly only natural distribution. That might be the explanation of Jesse Brodkin insistence that Anavex has fail on both primary measures. The situation with ADL is present in the phase 2a and i have published plot of changes in ADL as function of changes in MMSE showing almost no existing sensitivity in the range of cognition the patients experienced positive changes. That case is closed and explained away by the company. Mr Brodkin insists that no statistical significance has been achieved for cognition measure in Phase 2b/3. I wonder why as he probably inputs the means and SD for the placebo and dosed arm in software package whereas there is the case of skewed distribution that when entered patient by patient into a software package produced the reported statistical significance. Read my post on my patreon.com/Bio_Oko page.
Piotr Pietrzkiewicz BSME


[url][/url][tag]patreon.com/Bio_Oko[/tag]